Scholarlink

Objective <p>To estimate the added clinical benefit of extending transcutaneous tibial nerve stimulation (TTNS) from 12 to 24 weeks in pediatric overactive bladder (OAB), and to characterize late responders.</p> Patients and Methods <p>Prospective single-arm cohort with home-based TTNS and assessments at baseline, 12, and 24 weeks. The primary outcome was change in OAB Symptom Score (OABSS) and responder status defined by a minimal clinically important difference (MCID) of≥3 points. Paired responder transitions were tested with McNemar’s exact test and summarized as paired risk difference (RD) with 10,000-sample bootstrap 95% CIs; repeated-measures GEE/LMM were pre-specified for confirmatory modeling.</p> Results <p>Among 80 paired observations, 12→24-week transitions were 0→0: 13, 0→1: 14, 1→0: 0, 1→1: 53. The paired RD in responder rate (24w−12w) was 0.175 (95% CI 0.100–0.263; McNemar p=0.000122). Late response occurred in 14 of 27 (51.9%) 12-week nonresponders. Mean OABSS improved by 3.64±2.25 at 12 weeks and 5.14±2.63 at 24 weeks.</p> Conclusions <p>Extending TTNS to 24 weeks was associated with additional symptom improvement and a substantial proportion of late responders without loss of response. Findings suggest that continuing TTNS beyond 12 weeks may be considered for early nonresponders, pending confirmation in randomized, sham-controlled trials. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Extended-course transcutaneous tibial nerve stimulation for pediatric overactive bladder: a 6-Month prospective single-arm study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月4日

查看全文
  • Fangzheng Cheng,
  • Jian Wang,
  • Dongming Wang,
  • Pengxiang Wang,
  • Yunhe Zhang,
  • Guoxin Song

摘要

Objective

To estimate the added clinical benefit of extending transcutaneous tibial nerve stimulation (TTNS) from 12 to 24 weeks in pediatric overactive bladder (OAB), and to characterize late responders.

Patients and Methods

Prospective single-arm cohort with home-based TTNS and assessments at baseline, 12, and 24 weeks. The primary outcome was change in OAB Symptom Score (OABSS) and responder status defined by a minimal clinically important difference (MCID) of≥3 points. Paired responder transitions were tested with McNemar’s exact test and summarized as paired risk difference (RD) with 10,000-sample bootstrap 95% CIs; repeated-measures GEE/LMM were pre-specified for confirmatory modeling.

Results

Among 80 paired observations, 12→24-week transitions were 0→0: 13, 0→1: 14, 1→0: 0, 1→1: 53. The paired RD in responder rate (24w−12w) was 0.175 (95% CI 0.100–0.263; McNemar p=0.000122). Late response occurred in 14 of 27 (51.9%) 12-week nonresponders. Mean OABSS improved by 3.64±2.25 at 12 weeks and 5.14±2.63 at 24 weeks.

Conclusions

Extending TTNS to 24 weeks was associated with additional symptom improvement and a substantial proportion of late responders without loss of response. Findings suggest that continuing TTNS beyond 12 weeks may be considered for early nonresponders, pending confirmation in randomized, sham-controlled trials.